Senti Bio reports Q1 net loss $4.2M, secures up to $40M financing; FDA supports pivotal trial for SENTI-202 in R/R AML

Senti Biosciences, Inc.

Net loss $4.2M ($0.14/share) vs $14.1M year ago; cash $8.9M as of March 31, 2026.
Secured up to $40M in senior secured convertible notes from Celadon Partners; initial $10M tranche expected May 2026.
FDA RMAT meeting supports single-arm multi-center pivotal trial for SENTI-202 in R/R AML after LD chemotherapy.
Donor X phenotype identified: 50% cCR (7/14) with Donor X NK cells vs 12.5% (1/8) without; longest remission 21+ months.
Lease modification gain $6.9M; cash burn reduced to $7.5M Q1 2026 from $14.1M Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.